New Study Finds New Anti-Psychotics for Kids No Better Than Generics

A recent government study published in the American Journal of Psychiatry, has concluded that two of the most commonly prescribed atypical anti-psychotics, Janssen’s Risperdal and Eli Lilly’s Zyprexa, “neither performed any better in children and adolescents than an older generic drug.”

Such findings are significant, where as the New York Times reports, “prescription rates for the newer drugs, called atypical antipsychotics, have increased more than fivefold for children over the past decades and a half, and doctors now use them to settle outbursts and aggression in children with a wide variety of diagnoses, despite serious side effects.”

In light of this recent study, there is now significant question as to both the efficacy and effectiveness of new atypical anti-psychotics in children as compared to generics.

As Jon McClellan of the University of Washington, and co-author of the new study expressed, “I think the reason the use of these newer drugs has gone up so fast is that there was this widespread assumption that they were safer and more effective than what we had before … Well, we’re seeing now that that’s not the whole story.”